duvyzat

October 24, 2025

Italfarmaco Addresses Patient Deaths, DUVYZAT Safety Profile in Community Letter

Italfarmaco, the company that developed DUVYZAT® (givinostat), has shared a letter to the Duchenne muscular dystrophy community addressing concerns raised in recent online, community-based discussions about patient deaths involving individuals living with Duchenne who were…

Learn More

September 19, 2024

PPMD Community Webinar Recap: Overview of DUVYZAT and Access Resources

On September 18, 2024, PPMD hosted an informative community webinar featuring representatives from ITF Therapeutics, PPMD, and the Little Hercules Foundation. The session focused on DUVYZAT (givinostat), a recently approved HDAC inhibitor for the treatment…

Learn More

ITF Therapeutics Announces U.S. Commercial Availability of DUVYZAT™ (givinostat) for Treatment of Duchenne

PPMD is pleased to learn that DUVYZAT™ (givinostat) is now commercially available in the United States. DUVYZAT™ is a histone deacetylase (HDAC) inhibitor indicated for individuals diagnosed with Duchenne from six years of age and…

Learn More

Navigating the Approved Therapy Landscape

The approved therapy landscape has changed drastically in Duchenne, especially over the last year. With multiple newly approved therapies comes a lot of questions about how to navigate these drugs: when they are prescribed; who…

Learn More

ITF Therapeutics Shares Update on DUVYZAT™ Following FDA Approval

Following the FDA’s approval of DUVYZAT™ (givinostat) on March 21, 2024, ITF Therapeutics, LLC, the company responsible for producing and marketing DUVYZAT™ in the United States, today shared an update on the drug and related…

Learn More

FDA Grants Approval to DUVYZAT™ (Givinostat)

PPMD is excited to learn that the FDA has granted approval to DUVYZAT™ (givinostat), a histone deacetylase (HDAC) inhibitor indicated for individuals diagnosed with Duchenne muscular dystrophy from six years of age and older. DUVYZAT™…

Learn More

Join Our Mailing List